ATE299021T1 - Verwendung von oxazolidinonderivaten zur behandlung von psoriasis - Google Patents

Verwendung von oxazolidinonderivaten zur behandlung von psoriasis

Info

Publication number
ATE299021T1
ATE299021T1 AT02028171T AT02028171T ATE299021T1 AT E299021 T1 ATE299021 T1 AT E299021T1 AT 02028171 T AT02028171 T AT 02028171T AT 02028171 T AT02028171 T AT 02028171T AT E299021 T1 ATE299021 T1 AT E299021T1
Authority
AT
Austria
Prior art keywords
psoriasis
treatment
oxazolidinone derivatives
oxazolidinone
derivatives
Prior art date
Application number
AT02028171T
Other languages
English (en)
Inventor
Donald H Batts
Roger G Ulrich
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE299021T1 publication Critical patent/ATE299021T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02028171T 1997-11-18 1998-11-10 Verwendung von oxazolidinonderivaten zur behandlung von psoriasis ATE299021T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6568997P 1997-11-18 1997-11-18
US7129798P 1998-01-16 1998-01-16
US7524798P 1998-02-19 1998-02-19

Publications (1)

Publication Number Publication Date
ATE299021T1 true ATE299021T1 (de) 2005-07-15

Family

ID=34743570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02028171T ATE299021T1 (de) 1997-11-18 1998-11-10 Verwendung von oxazolidinonderivaten zur behandlung von psoriasis

Country Status (7)

Country Link
EP (1) EP1304107B1 (de)
AT (1) ATE299021T1 (de)
DE (1) DE69830811T2 (de)
DK (1) DK1304107T3 (de)
ES (1) ES2243650T3 (de)
PT (1) PT1304107E (de)
SI (1) SI1304107T1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398561C1 (ru) * 2008-12-19 2010-09-10 Государственное образовательное учреждение высшего профессионального образования "Дальневосточный государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ поэтапного лечения неопределенного типа течения псориаза
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (en) * 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones

Also Published As

Publication number Publication date
EP1304107B1 (de) 2005-07-06
EP1304107A3 (de) 2003-11-19
ES2243650T3 (es) 2005-12-01
EP1304107A2 (de) 2003-04-23
DE69830811T2 (de) 2006-04-27
DE69830811D1 (de) 2005-08-11
DK1304107T3 (da) 2005-08-22
PT1304107E (pt) 2005-09-30
SI1304107T1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69304843D1 (de) Methode zur Behandlung von Haarausfall
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE233092T1 (de) Verwendung von oxazolidinonderivate zur behandlung von arthritis
ATE299021T1 (de) Verwendung von oxazolidinonderivaten zur behandlung von psoriasis
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE59813136D1 (de) Verwendung von Thiaminen zur Herstellung eines Arzneimittels zur Prophylaxe und zur Therapie der diabetischen Retinopathie und der diabetischen Nephropathie
DE59709081D1 (de) Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit
DE3865283D1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1304107

Country of ref document: EP

REN Ceased due to non-payment of the annual fee